TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients experiencing a treatment-related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIH Examiner Flanker Task Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in NIH Examiner Set Shifting Task Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in NIH Examiner Dot Counting Task Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in NIH Examiner Unstructured Planning Task Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient engagement and participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of microbial species colonising medical device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Maximal Expiratory Pressure (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rates of bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rates of retinopathy of prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Metabolic bone disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reactive hyperemic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: muscle strength and functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary function and/or ventilation conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall patient satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Standardized Neurocognitive Function Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI Evidence of Silent Cerebral Infarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI Evidence of New Cerebral Micro-bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of fractions successfully delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) - Alertness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With New Onset and Worsening of Post-baseline Suicidality for Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) (All Causalities)
Endpoint domain: Adverse events/effects
Primary endpoint: Correctness rate of nurses in identifying risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of nurses using the SAD PERSONS Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous delivery without perineal lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of Inflammatory Cells in Skin Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change in Body Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Contact Lens-Corrected Visual Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripapillary RNFL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum ferritin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average number of pregnancies conceived
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Plasma concentration of free resveratrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 18F-fluciclovine PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of COVID-19 on the course of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of COVID-19 on psoriasis patients' behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratio of urinary FSH21/FSH24 and total FSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of serum estradiol and FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum lipids concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change of Total Eczema Area and Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal metabolite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of serum androstenedione level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RPTD) of ABBV-011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of Treatment Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With an Ongoing Pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With an Ongoing Pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Plasma lipids profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum bactericidal titers against meningococcal serogroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Virologic efficacy (HIV-1 viral load < 200 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related toxicity of Grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Gene expression changes in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24 hour urine protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in cognition from baseline at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in attention from baseline at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of coughing during emergence of general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Levels of Telapristone Acetate in Breast Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent Change in MMT Glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of Endothelialisation/Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from the measure of mental disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from the measure of Child mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from depression measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Posttraumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of details in memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Specificity of memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scores on QoR-40
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fraction of Pulseless Time With no Chest Compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airway management success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Roland-Morris Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects
Endpoint domain: Mortality/survival
Primary endpoint: change in oxygenation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of excess weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment response up to 2 months after ASCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toxicity (frequency of grade 3 or worse toxicities)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Patient-Reported Pain During the Procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient-Reported Anxiety During Procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child and Adult Medical Procedure Interaction Scale (CAMPIS) Score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: percentage of patients optimized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metacognitive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: non hypoxemic apnea time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Meconium Aspiration Syndrome
Endpoint domain: Mortality/survival
Primary endpoint: Four step square test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Koos
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in mean weekly pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Capacity with functional tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Markedly Abnormal Vital Signs Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Markedly Abnormal Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated dilation of the brachial artery (FMD) %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of the pilonidal sinus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locomotor Capabilities Index-5
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Response and Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Dose-Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of Trabectedin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct planes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average dice similarity coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High frequency normalized index (HFnu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Failure at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Strength of Self-Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Strength of Psychological Flexibility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fugl-Meyer Motor Assessment of the Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate relief of IBS pain & discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of peach allergic subjects at major risk of anaphylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spontaneous Vaginal Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 30 per cent reduction of rapid infancy weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed plasma concentration of encapsulated doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma-concentration-versus time curve from time 0 to time t of encapsulated doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma-concentration-versus time curve from time 0 to infinite time of encapsulated doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline muscle volume after 14 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline muscle strength of knee extensors after 14 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Measured ACP Content
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measured Patient Centeredness
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: NPD response patterns consistency with CF diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence (protocol feasibility)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline in Numeric Rating Scale of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intima media thickness in the carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaques in the carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprandial 2h blood glucose (2hPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FGF-21 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fibromyalgia Impact Questionnaire (FIQ) total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: nocturia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post void residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: detrusor pressure at maximum flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post-operative sagittal alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Memory Recall Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: completion of course of medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microbiological clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of social and interactive skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: HCA-DNA adducts in pancreatic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Units of blood products transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in heel broadband ultrasound attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIS at 12 Weeks Post Final Treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SCAT-5 Concussion Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pediatric Quality of Life Inventory (PedsQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone consolidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of urinary continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: recovery of erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Timed Sit-to-Stand (TSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of genetic variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of glabellar lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: favorable outcome measured by DES scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chest Tube Losses
Endpoint domain: Adverse events/effects
Primary endpoint: Change in supraspinatus, infraspinatous and subscapularis water:fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of nasogastric tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients receiving or referred for examination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chance to fall
Endpoint domain: Adverse events/effects
Primary endpoint: Pattern of pulmonary abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients experiencing heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurements of left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Management of posterior epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with one or more HMR mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infiltrating leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Prion protein autoantibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with hyperbaric oxygen treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Wear of antagonist natural enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PPI use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PTSD clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School absenteeism rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Fasting Plasma Glucose (FPG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of beta-hemolytic streptococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hysteroscopic Fluid Deficit (HFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum RV-IgA and RV-IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of bone marrow blasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: safety and DLTs
Endpoint domain: Adverse events/effects